Panbela Therapeutics, Inc.
PBLA · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $2 | $1,501 | $20,220 | $27,512 |
| - Cash | $2,578 | $1,285 | $11,867 | $9,022 |
| + Debt | $5,194 | $6,844 | $0 | $0 |
| Enterprise Value | $2,618 | $7,060 | $8,353 | $18,490 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$25,647 | -$35,731 | -$10,010 | -$5,754 |
| % Margin | – | – | – | – |
| EBITDA | -$51,294 | -$34,745 | -$10,611 | -$5,046 |
| % Margin | – | – | – | – |
| Net Income | -$25,263 | -$34,933 | -$10,135 | -$4,768 |
| % Margin | – | – | – | – |
| EPS Diluted | -232,429.55 | -40,748.57 | -20,773.7 | -14,798.1 |
| % Growth | -470.4% | -96.2% | -40.4% | – |
| Operating Cash Flow | -$25,249 | -$15,276 | -$6,704 | -$3,854 |
| Capital Expenditures | $0 | -$660 | $0 | $0 |
| Free Cash Flow | -$25,249 | -$15,936 | -$6,704 | -$3,854 |